Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
Launched by BRISTOL-MYERS SQUIBB · Feb 27, 2012
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Inclusion Criteria:
- Subjects with:
- • Confirmed Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
- • Not having received prior systemic treatment for advanced HCC
- • Normal or moderately impaired liver function (Child-Pugh Class A or B (CP total score of ≤ 7))
- • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Exclusion Criteria:
- Subjects with:
- • Brain metastasis or evidence of leptomeningeal disease
- • History of impaired brain function (encephalopathy) or active heart disease
- • Unmanageable fluid in the abdomen (ascites)
- • Bleeding esophageal or gastric varices within 2 months prior to inclusion
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Beijing, Beijing, China
Ha Erbin, Heilongjiang, China
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials